Survey of New, Small-Molecule Isatin-Based Oxindole Hybrids as Multi-Targeted Drugs for the Treatment of Alzheimer’s Disease
作者:Carolina S. Marques、Óscar López、Luisa Leitzbach、José G. Fernández-Bolaños、Holger Stark、Anthony J. Burke
DOI:10.1055/s-0041-1737343
日期:2022.10
has been very active at developing and assaying complex libraries of scaffolds with a focus on their potential to identify bioactive drug candidates for neurodegenerative diseases, particularly Alzheimer’s disease (AD). Attention has been focused on isatin-based oxindole scaffolds, for which promising results concerning butyrylcholinesterase (BuChE) inhibitory activity have previously been obtained.
在过去的十年中,我们小组一直非常积极地开发和分析复杂的支架库,重点是它们在识别神经退行性疾病,特别是阿尔茨海默病 (AD) 的生物活性候选药物方面的潜力。注意力一直集中在基于靛红的羟吲哚支架上,此前已经获得了有关丁酰胆碱酯酶 (BuChE) 抑制活性的有希望的结果。考虑到一些已发表的报告和对 AD 市售药物(强效胆碱酯酶 (ChE) 抑制剂)药效团的详细分析,我们对靛红核心进行了战略性结构修饰,并产生了一个新的基于靛红的羟吲哚杂化物家族(27 种新化合物) 在其框架中拥有关键的关键功能单元。合成是使用多种方法完成的,N-烷基化反应、铜催化胺化反应和点击化学。生成的文库在 ChE 和 MAO 酶上进行了评估,这两种酶都参与了神经退行性变的病理生理学。最佳抑制剂的IC 50值分别为 1.6 和 2.6 μM(BuChE 测定)。